Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02135874 · FLOW

Participant flow

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia · Source last updated 2024-03-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    See Detailed Description. Clofarabine: Given IV Cytarabine: Given IV Dexamethasone: Given IV Idarubicin: Given IV Rituximab: Given IV Sorafenib: Given PO Sorafenib Tosylate: Given PO Vincristine: Given IV Vincristine Sulfate: Given IV
    id
    FG000
    title
    Treatment (Combination Chemotherapy)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        16
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        16
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    See Detailed Description. Clofarabine: Given IV Cytarabine: Given IV Dexamethasone: Given IV Idarubicin: Given IV Rituximab: Given IV Sorafenib: Given PO Sorafenib Tosylate: Given PO Vincristine: Given IV Vincristine Sulfate: Given IV
    id
    FG000
    title
    Treatment (Combination Chemotherapy)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        16
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        16
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice